Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avacta GroupAVCTF 13 Debt-to-Equity is 6.02 as of Dec. 2025, which is 301% above its 10-year median of 1.50. GuruFocus rates AVCTF with a GF Score™ of 13/100 and a GF Value™ of $0.65 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 966 Biotechnology companies, Avacta Group ranks worse than 98.14% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Avacta Group's Debt-to-Equity or its related term are showing as below:
AVCTF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 1.5 Max: 6.03
Current: 6.03
During the past 13 years, the highest Debt-to-Equity Ratio of Avacta Group was 6.03. The lowest was 0.03. And the median was 1.50.
AVCTF's Debt-to-Equity is ranked worse than 98.14% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs AVCTF: 6.03
Avacta Group (OTCPK:AVCTF) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Avacta Group Debt-to-Equity Related Terms
Avacta Group Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Avacta Group's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVCTF vs VRTX, REGN, ALNY: Debt-to-Equity Comparison
For the Biotechnology subindustry, Avacta Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avacta Group Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avacta Group's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Avacta Group's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avacta Group (AVCTF) has a Debt-to-Equity of 6.02 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Avacta Group and its competitors. This is 301% above median its historical median of 1.50. Over the past decade, Avacta Group's Debt-to-Equity has ranged from 0.03 to 6.03. According to the industry distribution chart, Avacta Group ranks #948 out of 966 companies in the Biotechnology industry, placing it in the top 98.1%.
Is Avacta Group's Debt-to-Equity too high?
Avacta Group's current Debt-to-Equity of 6.02 is 301% above median its 10-year median of 1.50. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 6.03. The Biotechnology industry median Debt-to-Equity is 0.16. Avacta Group's value of 6.02 is 3662.5% above this industry median. Based on the distribution chart, Avacta Group ranks #948 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avacta Group has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avacta Group's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avacta Group ranks #948 out of 966 companies for Debt-to-Equity. This places Avacta Group in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Avacta Group's value of 6.02 is 3662.5% above this benchmark. Historically, Avacta Group's own Debt-to-Equity has ranged from 0.03 to 6.03 over the past decade. While the company's 10-year median is 1.50 vs. the industry median of 0.16, Avacta Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avacta Group's current Debt-to-Equity of 6.02 is 3662.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Avacta Group and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avacta Group's current Debt-to-Equity is 6.02, which is 301% above median its own 10-year median of 1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avacta Group stock overvalued right now?
Based on GuruFocus' analysis, Avacta Group (AVCTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.65, compared to a current price of $1.00 — trading 53.8% above its estimated fair value. The current Debt-to-Equity is 6.02, which is 301% above median its 10-year median of 1.50 and 3662.5% above the Biotechnology industry median of 0.16. Avacta Group's overall GF Score™ is 13/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Avacta Group (AVCTF), the current Debt-to-Equity is 6.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avacta Group (AVCTF) Overvalued in 2026?
Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued.
The current stock price of $1.00 is trading 53.8% above its estimated GF Value™ of $0.65.
GuruFocus considers Avacta Group to be Significantly Overvalued.
Key valuation signals for AVCTF:
Debt-to-Equity: 6.02 (301% above median its 10-year median of 1.50)
GF Value™: $0.65 vs. price of $1.00 (53.8% above fair value)
Industry Position: 3662.5% above the Biotechnology median (#948 of 966)
No single metric tells the full story. See the AVCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
13GF Score
Get the complete analysis for AVCTF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVCTF has been successfully added to your 
